Effects of Atorvastatin on Atherosclerosis and Atherogenesis in Systemic Lupus Erythematosus: A Pilot Study
Table 2
Baseline disease activity of patients.
Placebo ()
AT naïve ()
AT continuing ()
Organ involvement, n (%)
BILAG max
A
0 (0.0%)
0 (0.0%)
1 (20.0%)
B
5 (35.7%)
4 (26.7%)
0 (0.0%)
C
2 (14.3%)
3 (20.0%)
1 (20.0%)
D
7 (50.0%)
8 (53.3%)
3 (60.0%)
E
0 (0.0%)
0 (0.0%)
0 (0.0%)
(%) C or above
Constitutional
4 (28.6%)
0 (0.0%)
1 (20.0%)
Mucocutaneous
5 (35.7%)
3 (20.0%)
1 (20.0%)
Neurological
2 (14.3%)
3 (20.0%)
1 (20.0%)
Musculoskeletal
6 (42.9%)
5 (33.3%)
2 (40.0%)
Cardiorespiratory
1 (7.1%)
1 (6.7%)
0 (0.0%)
Gastrointestinal
1 (7.1%)
0 (0.0%)
0 (0.0%)
Ophthalmic
0 (0.0%)
0 (0.0%)
0 (0.0%)
Renal
0 (0.0%)
0 (0.0%)
0 (0.0%)
Haematological
1 (7.1%)
0 (0.0%)
0 (0.0%)
SLEDAI, median (IQR)
2.00 (0.00 to 6.50)
4.00 (0.00 to 6.00)
2.00#
SLICC total, median (IQR)
1.50 (0.75 to 3.00)
2.00 (0.00 to 3.00)
1.00#
(%) > 0
Ocular
2 (14.3%)
2 (13.3%)
0 (0.0)
Neurological
7 (50.0%)
8 (53.3%)
2 (40.0%)
Renal
1 (7.1%)
0 (0.0%)
1 (20.0%)
Pulmonary
2 (14.3%)
3 (20.0%)
0 (0.0%)
Cardiovascular
2 (14.3%)
1 (6.7%)
1 (20.0%)
Peripheral vascular
2 (14.3%)
1 (6.7%)
0 (0.0%)
Gastrointestinal
0 (0.0%)
0 (0.0%)
1 (20.0%)
Musculoskeletal
4 (28.5%)
4 (26.7%)
2 (40.0%)
Skin
0 (0.0%)
1 (6.7%)
0 (0.0%)
Gonadal failure
2 (14.3%)
1 (6.7%)
0 (0.0%)
Diabetes mellitus
0 (0.0%)
0 (0.0%)
1 (20.0%)
Malignancy
1 (7.1%)
1 (6.7%)
0 (0.0%)
AT: atorvastatin; BILAG: British Isles Lupus Assessment Group; SLEDAI: systemic lupus erythematosus disease activity index; SLICC: Systemic Lupus International Collaborative Clinics damage index; IQR: interquartile range. #IQR not calculated due to small sample size.
We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.
